Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 167 results for urinary tract infections

  1. Fever in under 5s: assessment and initial management (NG143)

    This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.

  2. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

  3. Embedding NICE guidance into GPSOC clinical systems

    optimisations which ensure that hypertension, CKD, AKI, asthma, urinary tract infections and diabetes are managed in accordance with...

  4. Colli-Pee for first void urine collection (MIB273)

    NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .

  5. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  6. Transvaginal laser therapy for urogenital atrophy (IPG697)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  7. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  8. Safeguarding adults in care homes (NG189)

    This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.

  9. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

  10. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

  11. Treatment for men with enlarged prostate is recommended by NICE for NHS adoption

    Final guidance from NICE recommends the PLASMA system

  12. Optilume for anterior urethral strictures (MIB241)

    NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .

  13. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

  14. World Antimicrobial Awareness Week: developing new models for the evaluation and purchase of antimicrobials

    Nick discusses World Antimicrobial Awareness Week and an important project he’s involved with to develop new models for the evaluation and purchase of antimicrobials.

  15. Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)

    Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam